Endometrial stromal sarcoma development after hysterectomy and tamoxifen therapy.
Tamoxifen therapy is well known for its success in adjuvant therapy for breast carcinoma; however, despite its benefits, the agents' estrogenic influence on the uterus, and subsequent endometrial cell proliferation may result in development of invasive uterine tumors. It has been estimated that tamoxifen may increase the risk of endometrial-based cancer two- to threefold, but uterine sarcomas remain relatively rare, accounting for 2 to 5 per cent of all uterine malignancies. We report the case of a 72-year-old woman having received tamoxifen for a breast carcinoma and having a hysterectomy nearly 30 years prior who presented with an intra-abdominal, omentum-based mass that on excision was identified as an endometrial stromal sarcoma.
Christie
D Benjamin
DB
Department of Surgery, Mercer University School of Medicine, Medical Center of Central Georgia, Macon, Georgia 31201, USA. benjie_christie@yahoo.com
Day
J Daniel
JD
Moore
Amy B
AB
Chapman
Jason R
JR
Nakayama
Don K
DK
Conforti
Arnold M
AM
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D018203:Sarcoma, Endometrial Stromal / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D013629:Tamoxifen / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed; D014594:Uterine Neoplasms / Q000628:therapy
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen